Bayer Kogenate FS
Bayer HealthCare, Biological Products Division

Contact Search Press Sitemap  
HomePatients & CaregiversHealthcare ProfessionalsPrescribing Information
Prescribing Information
Important Safety Information
Administration
HCP Video
Product Benefits
Hemophilia Awards
EZ-Log
EZ-Log Handheld
EZ-Log Web Client
Clinic Support
Bayer Factor Solutions
Rep Finder
Summer Camps
Patient Education Materials
HCP Resources
HCP FAQ
Bayer Links
Bayer Global
Living with Hemophilia
   General Conditions of Use
Privacy Statement
Imprint
  
 
  

Security/Privacy

With EZ-Log, patient data is private and secure.

  • Both the EZ-Log web application and the PDA are password protected and secure.

  • Data transmission to and from the EZ-Log server is encrypted.

  • Data collected and stored in the EZ-Log database is used only as agreed upon by the patient and healthcare providers.

  • Data is stored in secure data centers with systems and protocols in place to address standards for HIPAA and 21 CFR part 11.

PRIVACY OVERVIEW

Ownership and Use of Data
The infusion data collected and stored in the EZ-Log database is owned in the same manner as patient hand-written infusion data. As such, the data can only be used as agreed upon by the patient and healthcare professionals. The system's sponsor, Bayer HealthCare, has no access to the data and the database administrators (Arrowhead Electronic Healthcare) are strictly forbidden by contract and law to share any patient data with Bayer HealthCare.

Demographic Data
Patient privacy risks are minimized because EZ-Log was designed without any fields that contain demographic data. Instead, patient identification numbers are used to identify EZ-Log users. Only patient ID numbers, assigned by the clinic during the enrollment process, are displayed on the EZ-Log PDA and the EZ-Log web application. No other demographic data are stored in the EZ-Log database.

Roles
EZ-Log web application users are assigned to defined user groups, or roles. Thus the patient, clinic user, administrator, and pharmacy are given limited access to only those areas and functions of the web application that is appropriate.


Overview
Product Comparison
Market Research & Studies
EZ-Log Sign-in




Bayer Hemophila Awards
Bayer provides grants
to early career investigators, fellows in training, and other allied healthcare professionals.
Learn More


 
  

Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness, and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.

Please consult your health care provider prior to making any lifestyle changes. The images used on this site do not necessarily represent actual Hemophilia patients.